{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":31,"n_cols":5,"rows_kept":31,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[10,2,10,3],[11,2,11,3],[12,2,12,3],[13,2,13,3],[14,2,14,3],[17,2,17,3],[18,2,18,3],[22,2,22,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910965711903321"]
[null,null,"Titolo",null,"Review of the U.S. Army's health risk assessments for oral exposure to six chemical-warfare agents / / Subcommittee on Chronic Reference Doses for Selected Chemical Chemical-Warfare Agents, Committee on Toxicology, Board on Environmental Studies and Toxicology, Commission on Life Sciences, National Research Council"]
[null,null,"Pubbl/distr/stampa",null,"Washington, D.C., : National Academy Press, 1999"]
[null,null,"ISBN",null,"9786610185801"]
[{"$nulls":4},"9781280185809"]
[{"$nulls":4},"1280185805"]
[{"$nulls":4},"9780309539289"]
[{"$nulls":4},"0309539285"]
[{"$nulls":4},"9780585195674"]
[{"$nulls":4},"0585195676"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (320 p.)"]
[null,null,"Collana",null,"The Compass series"]
[null,null,"Disciplina",null,"615.9/51"]
[null,null,"Soggetti",null,"Chemical agents (Munitions) - Toxicology"]
[{"$nulls":4},"Chemical agents (Munitions) - Environmental aspects"]
[{"$nulls":4},"Health risk assessment"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Bibliographic Level Mode of Issuance: Monograph"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references."]
[null,null,"Nota di contenuto",null,"Review of the U.S. Army's Health Risk Assessments For Oral Exposure to Six Chemical-Warfare Agents -- Copyright -- OTHER REPORTS OF THE BOARD ON ENVIRONMENTAL STUDIES AND TOXICOLOGY -- Other Reports of the Committee on Toxicology -- Preface -- Contents -- Summary -- EVALUATION OF THE ARMY'S INTERIM RFDS AND SFS -- CONCLUSIONS AND RECOMMENDATIONS -- GA -- GB -- GD -- VX -- SULFUR MUSTARD -- LEWISITE -- 1 Introduction -- REFERENCES -- 2 Derivation of Reference Doses -- REFERENCE-DOSE CALCULATION -- BENCHMARK DOSE -- UNCERTAINTY FACTORS -- CONCLUSIONS -- REFERENCES -- 3 Evaluation of the Army's Interim Reference Dose for GA -- DERIVATION OF THE ARMY'S INTERIM RFD -- APPROPRIATENESS OF THE CRITICAL STUDY -- APPROPRIATENESS OF CRITICAL END POINT -- APPROPRIATENESS OF UNCERTAINTY FACTORS -- EXTRAPOLATION FROM ANIMAL TO HUMAN -- PROTECTING SUSCEPTIBLE SUBPOPULATIONS -- EXTRAPOLATION FROM LOAEL TO NOAEL -- "]
[{"$nulls":4},"EXTRAPOLATION FROM SUBCHRONIC TO CHRONIC EXPOSURES -- DATA-BASE ADEQUACY -- MODIFYING FACTOR FOR ADDITIONAL UNCERTAINTY -- SUMMARY -- WEIGHT AND STRENGTH OF EVIDENCE -- CONCLUSIONS -- DATA GAPS AND RESEARCH RECOMMENDATIONS -- REFERENCES -- 4 Evaluation of the Army's Interim Reference Dose for GB -- DERIVATION OF THE ARMY'S INTERIM RFD -- APPROPRIATENESS OF THE CRITICAL STUDY -- APPROPRIATENESS OF CRITICAL END POINT -- APPROPRIATENESS OF UNCERTAINTY FACTORS -- EXTRAPOLATION FROM ANIMAL TO HUMAN -- PROTECTING SUSCEPTIBLE SUBPOPULATIONS -- EXTRAPOLATION FROM LOAEL TO NOAEL -- EXTRAPOLATION FROM SUBCHRONIC TO CHRONIC EXPOSURES -- DATA-BASE ADEQUACY -- MODIFYING FACTOR FOR ADDITIONAL UNCERTAINTY -- SUMMARY -- WEIGHT AND STRENGTH OF EVIDENCE -- CONCLUSIONS -- DATA GAPS AND RESEARCH RECOMMENDATIONS -- REFERENCES -- 5 EVALUATION OF THE ARMY'S INTERIM REFERENCE DOSE FOR GD -- DERIVATION OF THE ARMY'S INTERIM RFD -- APPROPRIATENESS OF THE CRITICAL STUDY."]
[{"$nulls":4},"APPROPRIATENESS OF CRITICAL END POINT -- APPROPRIATENESS OF UNCERTAINTY FACTORS -- EXTRAPOLATION FROM ANIMAL TO HUMAN -- PROTECTING SUSCEPTIBLE SUBPOPULATIONS -- EXTRAPOLATION FROM LOAEL TO NOAEL -- EXTRAPOLATION FROM SUBCHRONIC TO CHRONIC EXPOSURES -- DATA-BASE ADEQUACY -- MODIFYING FACTOR FOR ADDITIONAL UNCERTAINTY -- SUMMARY -- WEIGHT AND STRENGTH OF EVIDENCE -- CONCLUSIONS -- DATA GAPS AND RESEARCH RECOMMENDATIONS -- REFERENCES -- 6 Evaluation of the Army's Interim Reference Dose for VX -- DERIVATION OF THE ARMY'S INTERIM RFD -- APPROPRIATENESS OF THE CRITICAL STUDY -- APPROPRIATENESS OF CRITICAL END POINT -- APPROPRIATENESS OF UNCERTAINTY FACTORS -- EXTRAPOLATION FROM ANIMAL TO HUMAN -- PROTECTING SUSCEPTIBLE SUBPOPULATIONS -- EXTRAPOLATION FROM LOAEL TO NOAEL -- EXTRAPOLATION FROM SUBCHRONIC TO CHRONIC EXPOSURES -- DATA-BASE ADEQUACY -- MODIFYING FACTOR FOR ADDITIONAL UNCERTAINTY -- SUMMARY -- WEIGHT AND STRENGTH OF EVIDENCE -- CONCLUSIONS -- DATA GAPS AND RESEARCH RECOMMENDATIONS -- REFERENCES -- 7 Evaluation of the Army's Interim Reference Dose and Slope Factor For Sulfur Mustard -- EVALUATION OF THE ARMY'S INTERIM RFD -- DERIVATION OF THE ARMY'S INTERIM RFD -- APPROPRIATENESS OF THE CRITICAL STUDY -- APPROPRIATENESS OF CRITICAL END POINT -- APPROPRIATENESS OF UNCERTAINTY FACTORS -- Extrapolation from Animal to Human -- Protecting Susceptible Subpopulations -- Extrapolation from LOAEL to NOAEL -- Extrapolation from Subchronic to Chronic Exposures -- Data-Base Adequacy -- Modifying Factor for Additional Uncertainty -- Summary -- WEIGHT AND STRENGTH OF EVIDENCE -- EVALUATION OF THE ARMY'S INTERIM CANCER SLOPE FACTOR -- DERIVATION OF THE ARMY'S INTERIM CANCER SLOPE FACTOR -- APPROPRIATENESS OF METHOD USED -- WEIGHT AND STRENGTH OF EVIDENCE -- CONCLUSIONS -- DATA GAPS AND RESEARCH RECOMMENDATIONS -- REFERENCES."]
[{"$nulls":4},"8 Evaluation of the Army's Interim Reference Dose for Lewisite -- DERIVATION OF THE ARMY'S INTERIM RFD -- APPROPRIATENESS OF THE CRITICAL STUDY -- APPROPRIATENESS OF CRITICAL END POINT -- APPROPRIATENESS OF UNCERTAINTY FACTORS -- EXTRAPOLATION FROM ANIMAL TO HUMAN -- PROTECTING SUSCEPTIBLE SUBPOPULATIONS -- EXTRAPOLATION FROM LOAEL TO NOAEL -- EXTRAPOLATION FROM SUBCHRONIC TO CHRONIC EXPOSURES -- DATA-BASE ADEQUACY -- MODIFYING FACTOR FOR ADDITIONAL UNCERTAINTY -- SUMMARY -- WEIGHT AND STRENGTH OF EVIDENCE "]
[{"$nulls":4},"-- CONCLUSIONS -- DATA GAPS AND RESEARCH RECOMMENDATIONS -- REFERENCES -- Glossary -- Appendix A Health Risk Assessment for The Nerve Agent GA -- HEALTH RISK ASSESSMENT FOR THE NERVE AGENT GA -- DISCLAIMER -- PREFACE -- TABLE OF CONTENTS -- LIST OF TABLES -- 1. INTRODUCTION -- 1.1. PHYSICAL/CHEMICAL PROPERTIES -- 1.2. ENVIRONMENTAL FATE -- 1.2.1 Air -- 1.2.2 Water -- 1.2.3 Soil -- 2. MECHANISM OF ACTION -- 2.1 Effects of Organophosphate Agents on the Nervous System -- 2.2 Effect on Blood Cholinesterases -- 2.2.1 Intra- and Interspecies Variation in Blood Cholinesterase Activity -- 2.2.2 Potency of Nerve Agents as Cholinesterase Inhibitors -- 3. TOXICOLOGY -- 3.1 Introduction -- 3.2 Acute Toxicity -- 3.3 Subchronic Toxicity -- 3.4 Chronic Toxicity -- 3.5 Nervous System Toxicity -- 3.6 Developmental and Reproductive Effects -- 3.7 Carcinogenicity -- 3.8 Genotoxicity -- 4. ORAL REFERENCE DOSE FOR GA -- 4.1 Cholinesterase Inhibition as an RfD Endpoint -- 4.2 Derivation of the Oral RfD for GA -- 4.3 Overall Confidence in the Oral RfD -- 4.4 Comparison of the Oral RfD with Human Toxicity Data -- 5. CARCINOGENICITY ASSESSMENT -- 6. REFERENCES CITED -- APPENDIX A -- APPENDIX B -- APPENDIX C -- Appendix B Health Risk Assessment for The Nerve Agent GB -- HEALTH RISK ASSESSMENT FOR THE NERVE AGENT GB -- DISCLAIMER -- PREFACE -- TABLE OF CONTENTS."]
[{"$nulls":4},"LIST OF TABLES -- 1. INTRODUCTION -- 1.1 PHYSICAL/CHEMICAL PROPERTIES -- 1.2. ENVIRONMENTAL FATE -- 1.2.1. Air -- 1.2.2 Water -- 1.2.3 Soil -- 2. MECHANISM OF ACTION -- 2.1 Effects of Organophosphate Agents on the Nervous System -- 2.2 Effect on Blood Cholinesterases -- 2.2.1 Intra- and Interspecies Variation in Blood Cholinesterase Activity -- 2.2.2 Potency of Nerve Agents as Cholinesterase Inhibitors -- 3. TOXICOLOGY -- 3.1 Introduction -- 3.2 Acute Toxicity -- 3.3 Subchronic Toxicity -- 3.4 Chronic Toxicity -- 3.5 Nervous System Toxicity -- 3.6 Developmental and Reproductive Effects -- 3.7 Carcinogenicity -- 3.8 Genotoxicity -- 4. ORAL REFERENCE DOSE FOR GB -- 4.1 Cholinesterase Inhibition as an RfD Endpoint -- 4.2 Derivation of the Oral RfD -- 4.3 Overall Confidence in the Oral RfD -- 4.4 Comparison of the RfD with Human Toxicity Data -- 5. CARCINOGENICITY ASSESSMENT -- 6. REFERENCES CITED -- APPENDIX A -- APPENDIX B -- Appendix C Health Risk Assessment for The Nerve Agent GD (Soman) -- HEALTH RISK ASSESSMENT FOR NERVE AGENT GD (SOMAN) -- DISCLAIMER -- PREFACE -- TABLE OF CONTENTS -- LIST OF TABLES -- 1. INTRODUCTION -- 1.1 PHYSICAL/CHEMICAL PROPERTIES -- 1.2 ENVIRONMENTAL FATE -- 1.2.1 Air -- 1.2.2 Water -- 1.2.3 Soil -- 2. MECHANISM OF ACTION -- 2.1 Effects of Organophosphate Agents on the Nervous System -- 2.2 Effect on Blood Cholinesterases -- 2.2.1 Intra-and Interspecies Variation in Blood Cholinesterase Activity -- 2.2.2 Potency of Nerve Agents as Cholinesterase Inhibitors -- 3. TOXICOLOGY -- 3.1 Introduction -- 3.2 Short-term Toxicity -- 3.3 Subchronic Toxicity -- 3.4 Chronic Toxicity -- 3.5 Nervous System Effects -- 3.6 Developmental and Reproductive Effects -- 3.7 Carcinogenicity and Genotoxicity -- 4. ORAL REFERENCE DOES FOR GD -- 4.1 Cholinesterase Inhibition as an RfD Endpoint -- 4.2 Derivation of the Oral RfD for GD."]
[{"$nulls":4},"4.3 Comparison of RfD with Toxicity Data -- 5. CARCINOGENICITY ASSESSMENT FOR GD -- 6. REFERENCES CITED -- APPENDIX A -- APPENDIX D Health Risk Assessment for The Nerve Agent VX -- HEALTH RISK ASSESSMENT FOR THE NERVE AGENT VX -- DISCLAIMER -- PREFACE -- TABLE OF CONTENTS -- LIST OF TABLES -- 1. INTRODUCTION -- 1.1. PHYSICAL/CHEMICAL PROPERTIES -- 1.2. "]
[{"$nulls":4},"ENVIRONMENTAL FATE -- 1.2.1 Air -- 1.2.2 Water -- 1.2.3 Soil -- 2. MECHANISM OF ACTION -- 2.1 Effects of Organophosphate Compounds on the Nervous System -- 2.2 Effect on Blood Cholinesterases -- 2.2.1 Intra- and Interspecies Variation in Blood Cholinesterase Activity -- 2.2.2 Potency of Nerve Agents as Cholinesterase Inhibitors -- 2.2.3 Cholinesterase Inhibition by VX -- 3. TOXICOLOGY -- 3.1 Introduction -- 3.2 Acute Toxicity -- 3.3 Subchronic Toxicity -- 3.4 Chronic Toxicity -- 3.5 Nervous System Toxicity -- 3.6 Developmental and Reproductive Effects -- 3.7 Carcinogenicity -- 3.8 Genotoxicity -- 4. ORAL REFERENCE DOSE FOR VX -- 4.1 Cholinesterase Inhibition as an RfD Endpoint -- 4.2 Derivation of the Oral RfD for VX -- 4.3 Overall Confidence in the RfD -- 4.4 Comparison of RfD with Human Toxicity Data -- 5. CARCINOGENICITY ASSESSMENT -- 6. REFERENCES CITED -- APPENDIX A -- APPENDIX B -- APPENDIX C -- APPENDIX C -- APPENDIX D -- Appendix E Health Risk Assessment for Sulfur Mustard (HD) -- HEALTH RISK ASSESSMENT FOR SULFUR MUSTARD (HD) -- DISCLAIMER -- PREFACE -- TABLE OF CONTENTS -- LIST OF TABLES -- 1. INTRODUCTION -- 1.1. PHYSICAL/CHEMICAL PROPERTIES -- 1.2. ENVIRONMENTAL FATE -- 1.2.1 Air -- 1.2.2 Water -- 1.2.3 Soil -- 2 MECHANISM OF ACTION -- 3. TOXICOLOGY -- 3.1 Introduction -- 3.2 Acute Toxicity -- 3.3 Subchronic Toxicity -- 3.4 Chronic Toxicity -- 3.4.1 Human Data -- 3.4.2 Animal Studies -- 3.5 Delayed Toxicity -- 3.6 Developmental and Reproductive Effects -- 3.7 Carcinogenicity."]
[{"$nulls":4},"3.7.1 Human Data."]